Skip to main content

Table 1 Baseline characteristics

From: Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma

  NULMS ULMS p value
  n (%) or median (range) n (%) or median (range)  
N 50 (100%) 45 (100%)  
Age at first diagnosis 61 (31-88) 54 (32-69) 0.002
Gender    <0.001
- Male 28 (56%)  
- Female 22 (44%) 45 (100%)  
Tumor stage    
- FIGO I 15 (33%)  
- FIGO III 3 (7%)  
- FIGO IV 27 (60%)  
Histological grade n = 47 n = 34 0.027
- G 1 1 (2%) 3 (9%)  
- G 2 + 3 46 (98%) 31 (91%)  
Tumor site n = 50   
- Extremities 30 (60%)  
- Abdominal 16 (32%)  
- Head/neck 2 (4%)  
- Thorax 2 (4%)  
Tumor size n = 50 n = 45 <0.001
cm 11.1 (3-40) 6.7 (3-14)  
- ≤5 cm 23 (46%) 6 (13%)  
- 5-10 cm 22 (44%) 14 (32%)  
- > 10.0 cm 5 (10%) 19 (42%)  
- Not evaluable 6 (13%)  
Tumor location n = 50   
- Deep/superficial 37 (74%)/13 (26%)  
Initial metastatic disease    0.007
- Yes 18 (36%) 30 (67%)  
Metastatic sites n = 18 n = 30
- Lung 14 (28%) 17 (38%)  
- Liver 7 (14%) 5 (11%)  
- Bone 4 (8%) 4 (9%)  
- Lymph nodes 3 (6%) 8 (18%)  
- Other 5 (10%) 15 (33%)  
Surgical resection    0.2
- Yes 47 (94%) 45 (100%)  
Resection margins n = 47 n = 45 0.048
- Wide 45 (96%) 37 (82%)  
- Marginal 2 (4%) 8 (18%)  
Re-resection    
- Yes 16 (34%)  
Pulmonary metastaseectomy    0.6
- Yes 6 (12%) 8 (18%)  
Radiationtherapy    0.04
- Yes 29 (58%) 16 (36%)  
Adjuvant Chemotherapy for initially localized disease   
- Yes 13 (41%) 8 (53%)  
Chemotherapy Regimen for initially localized disease   
- Epirubicine/ifosfamide 6 (46%) 3 (37%)  
- Doxorubicine 5 (39%) 1 (13%)  
- IFADIC 2 (15%) 2 (25%)  
- Gemcitabine/docetaxel 0 2 (25%)  
Relapse   
- No 12 (92%) 6 (75%)  
- Yes 1 (8%) 2 (25%)  
First line chemotherapy for initially metastastic disease   
- Yes 18 (36%) 27 (60%)  
First line chemotherapy regimen for initially metastastic disease n = 18 n = 27
- Doxorubicine 9 (50%) 7 (27%)  
- Epirubicine/ifosfamide 6 (33%) 2 (7%)  
- IFADIC 0 3 (11%)  
- Other 3 (17%) 2 (7%)  
- Gemcitabine/docetaxel 13 (48%)  
Response to first line Chemotherapy for initially metastastic disease n = 18 n = 27
- Complete remission 4 (22%) 2 (7%)  
- Partial remission 2 (11%) 3 (11%)  
- Stable disease 4 (22%) 4 (15%)  
- Progressive disease 7 (39%) 18 (67%)  
- Not evaluable 1 (6%)  
Follow-up time (months) 50 (1.2-153.7) 33 (1.5-269.1)  
Disease status    
Alive/dead 38 (76%)/12 (24%) 20 (44%)/25 (56%)  
  1. *Patients had initially localized disease; NULMS = non-uterine leiomyosarcoma; ULMS = uterine leiomyosarcoma.
  2. IFADIC = ifosfamide-doxorubicin-dacarbazine.